Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Angle Share News (AGL)
AGL Share
Price
AGL Share
News
AGL Share
Chat
AGL Share
Trades37
AGL
Live RNS
AGL Share
Charts
AGL Broker
Ratings
AGL Directors
Deals
AGL Financial
Diary
AGL
Fundamentals
AGL Short
Positions
AGL
Media
AGL Company
Research
AGL Company
Timeline
- There is currently no data for AGL
IN BRIEF: Angle highlights supportive data for DNA analysis tool
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Latest AGL News
- IN BRIEF: Angle hails publication of research data in science journal
23 Aug 2024 - UK shareholder meetings calendar - next 7 days
4 Jul 2024 - IN BRIEF: Angle says open offer raises proceeds of GBP500,000
21 Jun 2024 - EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows
5 Jun 2024 - Angle unveils plans to raise more than £10m
5 Jun 2024 - TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal
16 May 2024 - Angle reports promising results from Parsortix study
16 May 2024 - CORRECT: Angle shares up on assay development deal with AstraZeneca
3 May 2024
Related News
IN BRIEF: Angle names Peter Collins as interim CEO
(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...
Angle touts planned name and strategy change, Groen turns executive
(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...
IN BRIEF: Angle CEO and finance lead step down after shareholder talks
Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...
Angle News
IN BRIEF: Angle hails publication of research data in science journal
Angle PLC - Guildford, England-based liquid biopsy company - Celebrates research data on its Parsortix PC1 system that it says supports approval by th...
IN BRIEF: Angle says open offer raises proceeds of GBP500,000
Angle PLC - Guildford, England-based liquid biopsy company - Receives valid applications for a total of 3.6 million open offer shares from qualifying ...
EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...
Angle unveils plans to raise more than £10m
(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.
TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Angle reports promising results from Parsortix study
(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results...
CORRECT: Angle shares up on assay development deal with AstraZeneca
(Correcting company name in headline)
Follow the stocks
